PSMA PET for Improving the Diagnosis, Treatment, and Management of Prostate Cancer – AUA Abstract Review

Posted by E. David Crawford, MD | Dec 2022

David M. Albala, MD; E. David Crawford, MD; and Phillip J. Koo, MD, presented “PSMA PET for Improving the Diagnosis, Treatment, and Management of Prostate Cancer – AUA Abstract Review” for the Grand Rounds in Urology audience in December 2022.

How to cite: Albala, David M.; Crawford, E. David; Koo, Phillip J. “PSMA PET for Improving the Diagnosis, Treatment, and Management of Prostate Cancer – AUA Abstract Review.” December 2022. Accessed Apr 2024. https://grandroundsinurology.com/psma-pet-for-improving-the-diagnosis-treatment-and-management-of-prostate-cancer-aua-abstract-review/

PSMA PET for Improving the Diagnosis, Treatment, and Management of Prostate Cancer – AUA Abstract Review

In this discussion, supported by Lantheus, E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology and Professor of Urology at the University of California, San Diego, joins Philip J. Koo, MD, Division Chief of Diagnostic Imaging and Northwest Region Oncology Physician Executive at the Banner MD Anderson Cancer Center in Phoenix, Arizona, and David M. Albala, MD, Chief of Urology at Crouse Hospital in Syracuse, New York, to discuss seven abstracts from AUA 2022 highlighting PMSA PET imaging and the future of prostate cancer management. From PSMA-targeted fluorophore for improved cancer visualization to PSMA testing prior to salvage radiation therapy, the presenters cover a range of topics demonstrating the utility of PSMA PET imaging.

Works cited (in order of reference):

Meijer D, Eppinga W, Mohede R, et.al. Restaging Prostate-specific Membrane Antigen Positron Emission Tomography/ Computed Tomography is Associated with Improved Oncological Outcome in Men who Underwent Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer [AUA abstract PD22-02]. The Journal of Urology. 2022;Vol.207,No.5S,(suppl):e402.

Kuppermann D, Calais J, Brisbane W, et.al. Prostate biopsy targeted to Prostate Specific Membrane Antigen (PSMA) foci [AUA abstract MP09-20]. The Journal of Urology. 2022;Vol.207,No.5S,(suppl):e144.

Bahler C, Green M, Tann M, et.al. Predicting Extra-prostatic Extension (EPE) for surgical guidance in prostate cancer: A comparison of biopsy pathology, multiparametric MRI, and PSMA-PET [AUA abstract PD27-01]. The Journal of Urology. 2022;Vol.207,No.5S,(suppl):e493.

Nickols N, Berenji G, Kane N. Quantitative Piflufolastat F18 (PSMA) Scan Indices as a Response Imaging-Biomarker to Androgen Deprivation Therapy in Veterans with Newly Diagnosed Metastatic Prostate Cancer [AUA abstract PD35-04]. The Journal of Urology. 2022;Vol.207,No.5S,(suppl):e628.

Fleming, Mark. Impact of 18F-rhPSMA-7.3 PET on upstaging of patients with prostate cancer recurrence: Results from the prospective, phase 3, multicenter, SPOTLIGHT study [AUA abstract PLLBA-02]. The Journal of Urology. 2022;Vol.207,No.5S,(suppl):e1047.

Nguyen H, Antaris A, Van den Berg N. Results of the Phase 1 safety and efficacy Prostate Specific Membrane Antigen (PSMA) targeting fluorophore for image guided surgery in patients undergoing robotic prostatectomy [AUA abstract PD54-11]. The Journal of Urology. 2022;Vol.207,No.5S,(suppl):e920.

Scuderi S, Mazzone E, Gandaglia G. The Impact Of Histological Variants On The Performance Characteristics Of 68Ga-PSMA PET/CT In The Primary And Recurrent Setting [AUA abstract PD60-03]. The Journal of Urology. 2022;Vol.207,No.5S,(suppl):e1025.

Supported by

About the Authors

David Albala

David M. Albala, MD
Associated Medical Professionals
Syracuse, New York

Crawford2022_400px

E. David Crawford, MD
University of California San Diego
La Jolla, California

koo_400x400

Phillip J. Koo, MD
Banner MD Anderson Cancer Center
Phoenix, Arizona

About The Author

E. David Crawford, MD

Researcher-physician E. David Crawford, MD, has devoted his career in medicine to educating the public about men's health issues and finding effective techniques and procedures to address prostate cancer, the most common malignancy affecting men in the United States. He is currently a Professor of Urology and Jack A. Vickers Director of Prostate Research at the University of California, San Diego. Dr. Crawford received his medical degree from the University of Cincinnati and his postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship at the University of California Medical Center in Los Angeles. Dr. Crawford is an internationally recognized expert in benign prostate hypertrophy, urologic cancers, and in particular, prostate cancer. He has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone-refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 810 scientific articles, has published seven textbooks, authored over 60 book chapters, and provided more than 2,200 educational talks for patients and physicians. In an effort to raise public awareness about prostate health, Crawford in 1989 founded the Prostate Conditions Education Council (PCEC). The non-profit organization is comprised of a consortium of leading physicians, health educators, scientists, and men's health advocates. PCEC's advocacy for free or low-cost prostate screening has affected the lives of millions of American men. He currently chairs the PCEC. Crawford is an active member of many national and international organizations, including the American Society of Clinical Oncology, the American Urological Association (AUA), and the American Association for the Advancement of Science. Within the AUA, he has been a member of the Committee to Study Urologic Research Funding and the prostate cancer clinical trials subcommittee. Crawford served on the board of governors, the scientific advisory board of the Southwest Oncology Group, and was chairman of the Genitourinary Cancer Committee for 27 years. This group is the largest clinical trials group in the world. Crawford's involvement in the national prostate cancer arena has been widely recognized. He has received many honors and awards, including the CAP Cure Annual Award for Scientific Presentation in 1999 In 1997, he was presented with a 'Freddie Award" at the AMA International Health and Medical Film Competition for the program, ITV: The Cutting Edge Medical Report (Prostate Cancer: Understanding, Diagnosing, and Defeating), which Crawford hosted with special guest, retired General Norman Schwarzkopf. Crawford again won a prestigious 'Freddie Award" 5 years ago... He is a member of Best Doctors of America and was named Healthcare Provider of the Year in the Denver Metro area by the Denver Business Journal. He has been recognized as one of the Best Doctors of America for the past two decades and is recognized as one of the top 20 urologists in the country, for men, by Men’s Health Magazine. In 2018 he received the honor of being named the Distinguished Alumnus of the Year from the University of Cincinnati School of Medicine. In May of 2019, he received the Presidential citation from the American Urological Association recognizing for his “tireless role in genitourinary cancer research that has benefited countless urologic cancer patients.” He accepted the position of Editor in Chief of Grand Rounds in Urology in June of 2019. In 2021, he was the recipient of the Merle Stringer, M.D. annual award for excellence in medicine by the Florida State Medical Association.

Join the GRU Community

- Why Join? -

Share This

Chat with usLiveChat